JPMorgan Chase & Co. Reiterates “Overweight” Rating for AstraZeneca (LON:AZN)

JPMorgan Chase & Co. restated their overweight rating on shares of AstraZeneca (LON:AZN) in a report issued on Friday morning, MarketBeat reports. They currently have a £140 ($176.30) target price on the biopharmaceutical company’s stock.

Several other research analysts also recently commented on AZN. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a £110 ($138.52) target price on shares of AstraZeneca in a research note on Tuesday, September 3rd. Berenberg Bank reaffirmed a “buy” rating and set a £150 ($188.89) price objective on shares of AstraZeneca in a research report on Monday, September 2nd. Finally, Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of £104.12 ($131.12).

AstraZeneca Price Performance

LON:AZN opened at £104.22 ($131.24) on Friday. The stock has a market capitalization of £161.54 billion, a PE ratio of 3,325.08, a P/E/G ratio of 0.86 and a beta of 0.17. The firm has a fifty day simple moving average of £113.52 and a 200 day simple moving average of £120.66. AstraZeneca has a 1-year low of GBX 9,461 ($119.14) and a 1-year high of £133.88 ($168.59). The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 84.97.

Insider Buying and Selling at AstraZeneca

In related news, insider Pascal Soriot acquired 20,000 shares of the stock in a transaction that occurred on Thursday, November 14th. The stock was acquired at an average cost of £102.03 ($128.49) per share, for a total transaction of £2,040,600 ($2,569,701.55). Also, insider Michel Demare acquired 2,000 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The stock was bought at an average cost of GBX 118 ($1.49) per share, with a total value of £2,360 ($2,971.92). Insiders bought a total of 23,500 shares of company stock worth $223,316,000 over the last three months. Corporate insiders own 0.04% of the company’s stock.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.